耐多药结核贝达喹啉耐药出现评估:五年体外监测研究
DREAM 是一项为期五年(2015—2019)、覆盖 11 个国家的表型耐药监测研究,用 7H9 肉汤微量稀释法(BMD)和 7H10/7H11 琼脂稀释法(AD)检测 5,036 株贝达喹啉初治耐多药结核(MDR-TB)分离株对贝达喹啉及其他抗结核药物的敏感性。贝达喹啉敏感率 BMD 为 97.9%、AD 为 98.8%,耐药率分别为 0.6% 和 0.4%。
要点
- 贝达喹啉初治 MDR-TB 中耐药率低,BMD 0.6%、AD 0.4%
- BMD 流行病学折点 0.12 μg/ml,AD 为 0.25 μg/ml
- 贝达喹啉与氯法齐明交叉耐药率 MDR-TB 0.4%、pre-XDR/XDR 1%
核心结论
- 贝达喹啉初治 MDR-TB 人群中贝达喹啉耐药率低。
- 未发现与关键结核药物间存在限制治疗的交叉耐药或共同耐药模式。
研究设计与样本
- DREAM 为 2015—2019 年、覆盖 11 个国家的表型药物耐药监测研究。
- 纳入 5,036 株贝达喹啉初治 MDR-TB 分离株。
- 采用 7H9 肉汤微量稀释法(BMD)和 7H10/7H11 琼脂稀释法(AD)测定最低抑菌浓度(MIC)。
主要发现
- BMD 法贝达喹啉敏感、中间、耐药率分别为 97.9%、1.5%、0.6%。
- AD 法贝达喹啉敏感、中间、耐药率分别为 98.8%、0.8%、0.4%。
- 耐药率:氧氟沙星 35.1%、左氧氟沙星 34.2%、莫西沙星 33.3%、利奈唑胺 1.5%、氯法齐明 2%。
- 贝达喹啉与氯法齐明表型交叉耐药率在 MDR-TB 为 0.4%,在 pre-XDR-TB/XDR-TB 为 1%。
- 贝达喹啉与利奈唑胺、氯法齐明与利奈唑胺共同耐药率在 MDR-TB 分别为 0.1%、0.3%,在 pre-XDR-TB/XDR-TB 分别为 0.2%、0.4%。
关键数值与推荐
- BMD 流行病学折点值为 0.12 μg/ml,AD 为 0.25 μg/ml,与既往贝达喹啉折点一致。
- BMD 技术不确定区/中间类别设为 0.25 μg/ml,AD 设为 0.5 μg/ml。
- H37Rv 参考株贝达喹啉 AD MIC 质控范围未变,BMD MIC 质控范围调整为 0.015—0.12 μg/ml。
临床怎么用
- 对贝达喹啉初治 MDR-TB 分离株,可按 BMD 或 AD 法药敏结果判读贝达喹啉敏感性。
- 判读时注意 BMD 中间类别为 0.25 μg/ml、AD 为 0.5 μg/ml 的技术不确定区。
- 监测贝达喹啉与氯法齐明、利奈唑胺的交叉/共同耐药,尤其 pre-XDR-TB/XDR-TB 人群。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bedaquiline Drug Resistance Emergence Assessment in Multidrug-resistant tuberculosis (MDR-TB) (DREAM) was a 5-year (2015 to 2019) phenotypic drug resistance surveillance study across 11 countries. DREAM assessed the susceptibility of 5,036 MDR-TB isolates of bedaquiline treatment-naive patients to bedaquiline and other antituberculosis drugs by the 7H9 broth microdilution (BMD) and 7H10/7H11 agar dilution (AD) MIC methods. Bedaquiline AD MIC quality control (QC) range for the H37Rv reference strain was unchanged, but the BMD MIC QC range (0.015 to 0.12 μg/ml) was adjusted compared with ranges from a multilaboratory, multicountry reproducibility study conforming to Clinical and Laboratory Standards Institute Tier-2 criteria. Epidemiological cutoff values of 0.12 μg/ml by BMD and 0.25 μg/ml by AD were consistent with previous bedaquiline breakpoints. An area of technical uncertainty or intermediate category was set at 0.25 μg/ml and 0.5 μg/ml for BMD and AD, respectively. When applied to the 5,036 MDR-TB isolates, bedaquiline-susceptible, -intermediate, and -resistant rates were 97.9%, 1.5%, and 0.6%, respectively, for BMD and 98.8%, 0.8%, and 0.4% for AD. Resistance rates were the following: 35.1% ofloxacin, 34.2% levofloxacin, 33.3% moxifloxacin, 1.5% linezolid, and 2% clofazimine. Phenotypic cross-resistance between bedaquiline and clofazimine was 0.4% in MDR-TB and 1% in pre-extensively drug-resistant (pre-XDR-TB)/XDR-TB populations. Coresistance to bedaquiline and linezolid and clofazimine and linezolid were 0.1% and 0.3%, respectively, in MDR-TB and 0.2% and 0.4%, respectively, in pre-XDR-TB/XDR-TB populations. Resistance rates to bedaquiline appear to be low in the bedaquiline-treatment-naive population. No treatment-limiting patterns for cross-resistance and coresistance have been identified with key TB drugs to date.
引用
- Kaniga K, Hasan R, Jou R, et al. Bedaquiline Drug Resistance Emergence Assessment in Multidrug-Resistant Tuberculosis (MDR-TB): a 5-Year Prospective In Vitro Surveillance Study of Bedaquiline and Other Second-Line Drug Susceptibility Testing in MDR-TB Isolates. J Clin Microbiol. 2021. PMID: 34705538. doi:10.1128/JCM.02919-20
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。